	US 12,344,643 B2
	Compositions and methods for inhibition of FOXP3
James LaBelle, Chicago, IL (US); Rachel Eclov, Chicago, IL (US); Gregory Bird, Boston, MA (US); and Loren D. Walensky, Boston, MA (US)
Assigned to The University of Chicago, Chicago, IL (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 16/464,590
Filed by The University of Chicago, Chicago, IL (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Dec. 7, 2017, PCT No. PCT/US2017/065147 § 371(c)(1), (2) Date May 28, 2019, PCT Pub. No. WO2018/106937, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/431,147, filed on Dec. 7, 2016.
Prior Publication US 2021/0094990 A1, Apr. 1, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); C07K 1/107 (2006.01); C07K 14/73 (2006.01)

CPC C07K 14/4713 (2013.01) [C07K 1/1077 (2013.01); C07K 14/70514 (2013.01); A61K 38/00 (2013.01)]

13 Claims

1. A stapled alpha helical (SAH) peptide comprising at least 70% sequence identity to SEQ ID NO: 44 and being 31 or fewer amino acids in length, the peptide having a single hydrocarbon staple; wherein the SAH peptide is capable of inhibiting forkhead box P3 (FOX3P) oligomerization.